RecruitingPhase 2NCT07564479

Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

Evaluation of Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity in Oncology Patients

Sponsor

Minia University

Enrollment

50 participants

Start Date

Mar 10, 2026

Study Type

INTERVENTIONAL

Conditions

Nephrotoxicity Cisplatin Nephrotoxicity

Summary

To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Alpha-Lipoic Acid (ALA) for people with cisplatin nephrotoxicity and nephrotoxicity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAlpha-Lipoic Acid (ALA)

The intervention under investigation is the administration of oral Alpha-Lipoic Acid (ALA) as an adjunct to standard cisplatin-based chemotherapy.

Locations(1)

Minia University Hospital

Minya, Minya Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07564479

Related Trials

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

NCT070186221 location